Ignite Creation Date:
2024-05-06 @ 12:00 AM
Last Modification Date:
2024-10-26 @ 10:43 AM
Study NCT ID:
NCT01469182
Status:
COMPLETED
Last Update Posted:
2017-03-03
First Post:
2011-10-21
Brief Title:
A Study of Ragweed Ambrosia Artemisiifolia Allergy Immunotherapy Tablet in Adults With Ragweed Allergies P05751
Sponsor:
ALK-Abelló AS
Organization:
ALK-Abelló AS
Study Overview
Official Title:
A 28-Day Study Evaluating the Safety of Ragweed Ambrosia Artemisiifolia Allergy Immunotherapy Tablet SCH 39641MK-3641 Treatment in Ragweed Allergic Adults Phase 3 Protocol NoP05751
Status:
COMPLETED
Status Verified Date:
2017-01
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study assessed the safety profile of short ragweed Ambrosia artemisiifolia in participants with ragweed-induced rhinoconjunctivitis with or without asthma The primary objective was to compare treatment-emergent adverse events AEs for participants treated with short ragweed allergy immunotherapy tablet AIT with those treated with placebo
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| MK-3641 | OTHER | Merck | None |